NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
Osimertinib improves PFS in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) that has been treated with chemoradiotherapy and may be a new standard of care for this population, suggests the results of the international phase 3 LAURA trial presented at the 2024 ASCO Annual Meeting.
“There are currently no approved targeted treatments specifically for unresectable stage III EGFRm NSCLC. With the superior efficacy results along with the robust magnitude of benefit in the LAURA study, osimertinib provides a solution to a large unmet need for this patient population,” said lead study author Dr Suresh S Ramalingam, FASCO, Winship Cancer Institute of Emory University, Atlanta, Georgia, US.
The LAURA trial enrolled people with unresectable stage III NSCLC with EGFR mutations without any disease progression during/after definitive platinum-based chemoradiotherapy. People were randomly assigned on a two-to-one basis to receive osimertinib (143 patients) or a placebo (73 patients).
Osimertinib significantly improved PFS compared with placebo. The median PFS was 39 months in the osimertinib group vs six months with the placebo group.
In the osimertinib group, 74 per cent of participants did not have any cancer growth after 12 months and 65 per cent did not have any cancer growth after 24 months. This is compared with 22 per cent and 13 per cent in the placebo group, respectively.
Osimertinib showed a higher objective response rate when compared with placebo (57 vs 33 per cent, respectively).
The rate of new metastases to the brain was lower in the osimertinib arm (8 per cent) when compared with placebo (29 per cent).
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Studies presented at the ESMO Gastrointestinal Cancers Congress 2024 could improve outcomes through better patient selection...
Polymyalgia rheumatica is a chronic inflammatory disease affecting the connective vascular tissue.Pain, along with morning stiffness,...
ADVERTISEMENT
There is a lot of publicity given to the Volkswagen Golf, which is celebrating 50 years...
As older doctors retire, a new generation has arrived with different professional and personal priorities. Around...
Catherine Reily examines the growing pressures in laboratory medicine and the potential solutions,with a special focus...
The highlight of this year’s Irish Society for Rheumatology (ISR) Autumn Meeting was undoubtedly the...
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.